Noble Financial reaffirmed their buy rating on shares of Dyadic International (OTCMKTS:DYAI) in a research note issued to investors on Sunday, reports. Noble Financial currently has a $9.00 target price on the biotechnology company’s stock.

Separately, TheStreet upgraded Dyadic International from a d rating to a c rating in a research report on Wednesday, April 17th.

OTCMKTS:DYAI opened at $4.31 on Friday. Dyadic International has a 12-month low of $1.40 and a 12-month high of $4.87. The stock has a market cap of $115.13 million, a P/E ratio of -25.35 and a beta of 0.29.

About Dyadic International

Dyadic International, Inc, a biotechnology platform company, engages in the development, production, and sale of enzymes and other proteins in the United States and the Netherlands. It utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial production of human and animal vaccines, monoclonal antibodies, bi-specific antibodies, fab antibody fragments, FC-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins.

Recommended Story: What is intrinsic value?

Receive News & Ratings for Dyadic International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyadic International and related companies with's FREE daily email newsletter.